logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
CDTX
Cidara Therapeutics, Inc.
221.38
2 x 156.95
2 x 282.00
bid
ask
+
0.00
0.00%
09:30 AM
Ytd0.22%
1y725.74%
221.38
day range
221.38
15.22
52 week range
221.42
Open221.38Prev Close221.38Low221.38High221.38Mkt Cap5.61B
Vol2.69MAvg Vol1.37MEPS-11.20P/E-19.77Forward P/E5.75
Beta1.53Short Ratio1.34Inst. Own103.89%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0650-d Avg187.66200-d Avg84.671yr Est221.50

CDTX News

Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
defenseworld.net
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You S

Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) shares crossed above its 50-day moving av

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
feeds.benzinga.com
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock So

Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug

3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank
defenseworld.net
3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank

ANB Bank bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) during the unde

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts
defenseworld.net
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts

Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) has been assigned a consensus recommendat

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
fool.com
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

HighVista Strategies initiated a position in Cidara Therapeutics, buying 70,904 shares valued at $6.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages
defenseworld.net
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages

Shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) have received a consensus recom

3 Potential Mid-Cap Biotech Buyout Targets In 2026
seekingalpha.com
3 Potential Mid-Cap Biotech Buyout Targets In 2026

The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two

Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX
defenseworld.net
Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX

Geode Capital Management LLC grew its position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX)

Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
prnewswire.com
Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN
globenewswire.com
HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS,

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorn

hVIVO gains validation from Cidara's takeover; broker calls it a "glowing endorsement"
proactiveinvestors.co.uk
hVIVO gains validation from Cidara's takeover; broker calls it a "glowing endorsement"

Merck's agreement to acquire Cidara Therapeutics for about $9.2 billion gives hVIVO PLC (AIM:HVO) a

hVIVO hails $9.2 billion Cidara takeover after key trial wins
proactiveinvestors.co.uk
hVIVO hails $9.2 billion Cidara takeover after key trial wins

hVIVO PLC (AIM:HVO) has praised its long-running partner Cidara Therapeutics after the American biot

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
globenewswire.com
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Preventio

Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysi

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS,

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & A

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
fool.com
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
fool.com
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?

The pharmaceutical giant's post-Keytruda plans continue to take shape.

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
fool.com
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Rep

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
forbes.com
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything
marketbeat.com
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

In one of the most decisive strategic moves in the biotech sector this year, pharmaceutical titan Me

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
fool.com
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soar

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

Earnings Scheduled For November 6, 2025
benzinga.com
Earnings Scheduled For November 6, 2025
benzinga.com
Earnings Scheduled For August 7, 2025
benzinga.com
Earnings Scheduled For May 8, 2025
benzinga.com
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day S

Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead en
benzinga.com
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018
benzinga.com
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018
benzinga.com
Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018

Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018
benzinga.com
Stocks Which Set New 52-Week Low Yesterday, October 23rd

Stocks Which Set New 52-Week Low Yesterday, October 23rd